Illumina Inc. cut its full-year adjusted profit guidance for the second time in three months as it grapples with the impact ...

Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles. Read how ILMN ...

Q1 2025 Management View CEO Jacob Thaysen highlighted that Q1 revenue and EPS came in at the upper end of guidance. He emphasized the strong performance of the NovaSeq X instruments, with over 60 ...

Illumina lowered its full-year outlook as a result of increased costs tied to tariffs. The maker of gene-sequencing equipment and services said Thursday it anticipates $85 million in tariff related ...

The DNA sequencing company also cut its 2025 earnings outlook to reflect the impact of tariffs on its business.

Good day, ladies and gentlemen, and welcome to the first-quarter 2025 Illumina earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would ...

Illumina Inc (ILMN) reports strong cash flow and innovation pipeline amidst macroeconomic pressures and revised guidance.

In February, Illumina announced it would be laying off 96 San Diego workers.

U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb ...

Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin of 15.8% and non-GAAP operating ...